Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that new data indicates a systemic immune response can be triggered by its lead product candidate, PH-762, after local administration. These findings will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington, D.C. from November 10-14, 2021. The relevant poster presentation is scheduled for November 12, 2021, at 7:00 am ET, showcasing potential advancements in immuno-oncology therapy.
- None.
- None.
MARLBOROUGH, Mass., Oct. 18, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that new data suggesting a systemic immune response can be generated with its lead clinical product candidate, PH-762, after local administration. These data will be presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, being held in Washington, D.C. on November 10-14, 2021.
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Presentation Details are as follows: | |
Title: | Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model |
Abstract Number: | 869 |
Author: | Benjamin Cuiffo, et al. |
Time and Date: | 7:00 am - 8:30 pm ET on 11/12/2021 |
Location: | Poster Hall - Hall E |
Poster presentations will be accessible in person and virtually. Posters will released on the SITC website at 7:00 am ET on November 12, 2021 and will also be made available on the "Investors – Events and Presentations" section of the Company's website (click here).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by the ongoing coronavirus pandemic, the development of our product candidates, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, results from our preclinical and clinical activities, the timing or likelihood of regulatory filings and approvals, our ability to manufacture and supply our product candidates for clinical activities and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact Phio Pharmaceuticals Corp.
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
LifeSci Advisors
arr@lifesciadvisors.com
View original content:https://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-presentation-at-the-sitc-36th-annual-meeting-301401738.html
SOURCE Phio Pharmaceuticals Corp.
FAQ
What is the significance of PH-762 in Phio Pharmaceuticals' research?
When will Phio Pharmaceuticals present data on PH-762?
Where will the SITC 36th Annual Meeting take place?
What is the title of the presentation regarding PH-762?
Who is the author of the presentation on PH-762?
